ALPHARETTA, Ga., July 18, 2016 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCQB:SNWV), announced today that the Company will have a podium presentation at the Center for Biofilm Engineering’s 2016 Biofilm Science and Technology Meeting held at Montana State University in Bozeman, Montana on July 19-21, 2016.
SANUWAVE’s patented shock wave technology showed very promising results in removing difficult to eradicate medical biofilms created by both Gram-negative and Gram-positive species (Pseudomonas aeruginosa and Staphylococcus aureus) in tests performed by the Center for Biofilm Engineering at Montana State University. Other tests performed by the Center for Biofilm Engineering on marine biofilms formed from seawater organisms (provided by the Naval Research Laboratory) showed that shock wave technology is also completely removing these non-medical biofilms. Furthermore, our shock wave technology demonstrated bacterial killing in tests performed at University of Georgia. As a guest speaker, Dr. Iulian Cioanta, SANUWAVE’s Vice President of Research and Development, will present these results to the meeting participants in Session 2 – Industrial Biofilms, as part of the podium presentation titled “Acoustic pressure shock wave technology successfully disrupts medical and non-medical biofilms.”
“The fact that SANUWAVE was invited to present our results on biofilms removal and bacterial killing at this prestigious and exclusively focused conference on biofilms represents a great opportunity for the Company to show the extended capabilities of our technology and at the same time, emphasizes the interest of the biofilm experts in the effects of shock waves on eradication of bacteria or bacterial biofilms. We will take this opportunity to extend the reach of our technology in new fields and to begin exploring strategic partnerships to use our shock wave technology in biofilm reduction or elimination for specific industrial or medical applications, which represents a significant market opportunity for the Company,” commented Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE.
SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 52 patents (issued or pending) in the field of shock waves used in medical and non-medical applications.
About the Center for Biofilm Engineering
Montana State University’s Center for Biofilm Engineering has been a world leader in biofilm research for more than 20 years. A prestigious 11-year National Science Foundation Engineering Research Center grant awarded in 1990 paved the way for the CBE’s influence in the emerging field of biofilm research. The Center’s three-fold emphasis in research, education, and industry continues to produce results and exciting opportunities for students, staff, and faculty—as well as industrial partners.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact: Millennium Park Capital LLC Christopher Wynne 312-724-7845 email@example.com SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 firstname.lastname@example.org